ProfileGDS5678 / 1423391_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 88% 86% 89% 88% 85% 87% 85% 85% 88% 89% 89% 89% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.6348187
GSM967853U87-EV human glioblastoma xenograft - Control 26.8619888
GSM967854U87-EV human glioblastoma xenograft - Control 36.5345686
GSM967855U87-EV human glioblastoma xenograft - Control 47.2101489
GSM967856U87-EV human glioblastoma xenograft - Control 56.896688
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.1585185
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.4933287
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3612585
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.389885
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8551488
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.9754789
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.1047389
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.9949189
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.0276789